HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,201-7,212 of 27,277
Drug study icon
TerminatedEUCTR 2017-002232-16

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In United Kingdom
DepressionHistorical research record
Countries
United Kingdom
Sponsor
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd
Drug study icon
CompletedEUCTR 2004-003781-14

A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolarity type I,...

Official study title

A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder,...

Original registry wording; source language not specified.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Austria
BipolarityHistorical research record
Countries
Austria, Slovakia, Spain
Sponsor
Johnson & Johnson Pharmaceutical Research and Development
Drug study icon
CompletedNCT05693935

TV-44749 for schizophrenia

What is this study about?

Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Bentonville
SchizophreniaMedication studyAges 18–64
Countries
United States, Bulgaria, China, + 2 others
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Drug study icon
TerminatedNCT00997087

A study of Flumazenil for OCD

Official study title

Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.

This study ended early.

In Birmingham
OCDMedication studyAges 19–60
Countries
United States
Sponsor
Parkway Medical Center
Drug study icon
CompletedEUCTR 2012-000418-13

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In United Kingdom
SchizophreniaHistorical research record
Countries
United Kingdom
Sponsor
AbbVie Deutschland GmbH & Co. KG
Drug study icon
TerminatedEUCTR 2012-005000-17

A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Bulgaria
OCDHistorical research record
Countries
United Kingdom, Bulgaria, Czechia, + 1 other
Sponsor
Novartis Pharma Services AG

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.